Jim Wassil - 19 Sep 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Operating Officer
Signature
Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
PCVX
Transactions as of
19 Sep 2022
Transactions value $
-$66,335
Form type
4
Filing time
21 Sep 2022, 18:07:14 UTC
Previous filing
07 Sep 2022
Next filing
19 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $6.78K +2.8K +6.61% $2.42* 45.1K 19 Sep 2022 Direct
transaction PCVX Common Stock Sale -$69.9K -2.68K -5.94% $26.09 42.5K 19 Sep 2022 Direct F1, F2
transaction PCVX Common Stock Sale -$3.19K -120 -0.28% $26.56 42.3K 19 Sep 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -2.8K -1.23% $0.00 225K 19 Sep 2022 Common Stock 2.8K $2.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $25.56 to $26.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.